Endocannabinoid regulation of acute and protracted nicotine withdrawal: Effect of FAAH inhibition

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Cippitelli, Andrea ^a   Astarita, Giuseppe ^b   Duranti, Andrea ^c   Caprioli, Giovanni ^a   Ubaldi, Massimo ^a   Stopponi, Serena ^a   Kallupi, Marsida ^a   Sagratini, Gianni ^a   de Fonseca, F Rodrìguez ^d   Piomelli, Daniele ^b,e   Ciccocioppo, Roberto ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF URBINO   (Italy)

^d HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^e ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; FATTY ACID AMIDASE; NICOTINE;

AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN LEVEL; BRAIN TISSUE; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME INHIBITION; HIPPOCAMPUS; HYPOTHALAMUS; INTRACELLULAR SIGNALING; LOCOMOTION; LONG TERM EXPOSURE; MALE; MAZE TEST; MICROMORPHOLOGY; NEGATIVE FEEDBACK; NONHUMAN; PREFRONTAL CORTEX; RAT; SIGNAL TRANSDUCTION; TOBACCO DEPENDENCE; WEIGHT GAIN; WITHDRAWAL SYNDROME;

ACUTE DISEASE; AMIDOHYDROLASES; ANIMALS; ANXIETY; ARACHIDONIC ACIDS; BENZAMIDES; BRAIN; CANNABINOID RECEPTOR MODULATORS; CARBAMATES; COTININE; ENDOCANNABINOIDS; GLYCERIDES; IMPLANTS, EXPERIMENTAL; LOCOMOTION; MALE; MAZE LEARNING; NICOTINE; POLYUNSATURATED ALKAMIDES; RATS; RATS, WISTAR; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE CESSATION PRODUCTS; WEIGHT GAIN;

EID: 82355193789     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028142     Document Type: Article

References (73)

1. WHO (2002) The World Health Report 2002: Reducing Risk, Promoting Healthy Life. Geneve.
2. Risner ME, Goldberg SR, (1983) A comparison of nicotine and cocaine self-administration in the dog: Fixed-ratio and progressive ratio schedules of intravenous drug infusion. J Pharmavol Exp Ther 224: 319-326.
3. Pomerleau OF, (1986) Nicotine as a psychoactive drug: anxiety and pain reduction. Psychopharmacol Bull 22: 865-869.
4. Watkins SS, Stinus L, Koob GF, Markou A, (2000) Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J Pharmacol Exp Ther 292: 1053-1064.
5. Kenny PJ, Markou A, (2001) Neurobiology of the nicotine withdrawal syndrome. Pharmacol Biochem Behav 70: 531-549.
6. Hughes JR, Gust SW, Skoog K, Keenan RM, Fenwick JW, (1991) Symptoms of tobacco withdrawal. A replication and extension. Arch Gen Psychiatry 48: 52-59.
7. Schneider NG, Jarvik ME, Forsythe AB, (1984) Nicotine vs. placebo gum in the alleviation of withdrawal during smoking cessation. Addict Behav 9: 149-156.
8. Hughes JR, (2007) Effects of abstinence from tobacco: etiology, animal models, epidemiology, and significance: a subjective review. Nicotine Tob Res 9: 329-339.
9. Miksys S, Hoffmann E, Tyndale RF, (2000) Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. Biochem Pharmacol 59: 1501-1511.
10. O'Dell LE, Chen SA, Smith RT, Specio SE, Balster RL, et al. (2007) Extended access to nicotine self-administration leads to dependence: Circadian measures, withdrawal measures, and extinction behavior in rats. J Pharmacol Exp Ther 320: 180-193.
11. Malin DH, Lake JR, Newlin-Maultsby P, Roberts LK, Lanier JG, et al. (1992) Rodent model of nicotine abstinence syndrome. Pharmacol Biochem Behav 43: 779-784.
12. Hildebrand BE, Nomikos GG, Bondjers C, Nisell M, Svensson TH, (1997) Behavioral manifestations of the nicotine abstinence syndrome in the rat: peripheral versus central mechanisms. Psychopharmacology (Berl) 129: 348-356.
13. Slawecki CJ, Ehlers CL, (2002) Lasting effects of adolescent nicotine exposure on the electroencephalogram, event related potentials, and locomotor activity in the rat. Brain Res Dev Brain Res 138: 15-25.
14. Bura SA, Burokas A, Martin-Garcia E, Maldonado R, (2010) Effects of chronic nicotine on food intake and anxiety-like behaviour in CB(1) knockout mice. Eur Neuropsychopharmacol 20: 369-378.
15. Balerio GN, Aso E, Berrendero F, Murtra P, Maldonado R, (2004) Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. Eur J Neurosci 20: 2737-2748.
16. Merritt LL, Martin BR, Walters C, Lichtman AH, Damaj MI, (2008) The endogenous cannabinoid system modulates nicotine reward and dependence. J Pharmacol Exp Ther 326: 483-492.
17. Damaj MI, Kao W, Martin BR, (2003) Characterization of spontaneous and precipitated nicotine withdrawal in the mouse. J Pharmacol Exp Ther 307: 526-534.
18. Berrendero F, Mendizabal V, Robledo P, Galeote L, Bilkei-Gorzo A, et al. (2005) Nicotine-induced antinociception, rewarding effects, and physical dependence are decreased in mice lacking the preproenkephalin gene. J Neurosci 25: 1103-1112.
19. Epping-Jordan MP, Watkins SS, Koob GF, Markou A, (1998) Dramatic decreases in brain reward function during nicotine withdrawal. Nature 393: 76-79.
20. Suzuki T, Ise Y, Maeda J, Misawa M, (1999) Mecamylamine-precipitated nicotine-withdrawal aversion in Lewis and Fischer 344 inbred rat strains. Eur J Pharmacol 369: 159-162.
21. Maldonado R, Berrendero F, (2010) Endogenous cannabinoid and opioid systems and their role in nicotine addiction. Curr Drug Targets 11: 440-449.
22. Picciotto MR, Caldarone BJ, King SL, Zachariou V, (2000) Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology 22: 451-465.
23. Revuelta AV, Moroni F, Cheney DL, Costa E, (1978) Effect of cannabinoids on the turnover rate of acetylcholine in rat hippocampus, striatum and cortex. Naunyn Schmiedebergs Arch Pharmacol 304: 107-110.
24. Tripathi HL, Vocci FJ, Brase DA, Dewey WL, (1987) Effects of cannabinoids on levels of acetylcholine and choline and on turnover rate of acetylcholine in various regions of the mouse brain. Alcohol Drug Res 7: 525-532.
25. Acquas E, Pisanu A, Marrocu P, Di Chiara G, (2000) Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo. Eur J Pharmacol 401: 179-185.
26. Castane A, Valjent E, Ledent C, Parmentier M, Maldonado R, et al. (2002) Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 43: 857-867.
27. Castane A, Berrendero F, Maldonado R, (2005) The role of the cannabinoid system in nicotine addiction. Pharmacol Biochem Behav 81: 381-386.
28. Cohen C, Kodas E, Griebel G, (2005) CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav 81: 387-395.
29. Le Foll B, Goldberg SR, (2004) Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport 15: 2139-2143.
30. Forget B, Hamon M, Thiebot MH, (2005) Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats. Psychopharmacology (Berl) 181: 722-734.
31. Balerio GN, Aso E, Maldonado R, (2006) Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology (Berl) 184: 504-513.
32. Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, et al. (2005) The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 40: 2-14.
33. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, et al. (2005) Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313: 352-358.
34. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76-81.
35. Mor M, Rivara S, Lodola A, Plazzi PV, Tarzia G, et al. (2004) Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem 47: 4998-5008.
36. Cippitelli A, Cannella N, Braconi S, Duranti A, Tontini A, et al. (2008) Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat. Psychopharmacology (Berl) 198: 449-460.
37. Winders SE, Grunberg NE, Benowitz NL, Alvares AP, (1998) Effects of stress on circulating nicotine and cotinine levels and in vitro nicotine metabolism in the rat. Psychopharmacology (Berl) 137: 383-390.
38. Levin ED, Morgan MM, Galvez C, Ellison GD, (1987) Chronic nicotine and withdrawal effects on body weight and food and water consumption in female rats. Physiol Behav 39: 441-444.
39. Pellow S, Chopin P, File SE, Briley M, (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14: 149-167.
40. De Boer SF, Koolhaas JM, (2003) Defensive burying in rodents: ethology, neurobiology and psychopharmacology. Eur J Pharmacol 463: 145-161.
41. Treit D, Pinel JP, Fibiger HC, (1981) Conditioned defensive burying: a new paradigm for the study of anxiolytic agents. Pharmacol Biochem Behav 15: 619-626.
42. Cannich A, Wotjak CT, Kamprath K, Hermann H, Lutz B, et al. (2004) CB1 cannabinoid receptors modulate kinase and phosphatase activity during extinction of conditioned fear in mice. Learn Mem 11: 625-632.
43. Paxinos G, Watson C, (1998) The Rat Brain in Stereotaxic Coordinates, 4th Edition San Diego Academic Press.
44. Giuffrida A, Rodriguez de Fonseca F, Piomelli D, (2000) Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. Anal Biochem 280: 87-93.
45. Slawecki CJ, Gilder A, Roth J, Ehlers CL, (2003) Increased anxiety-like behavior in adult rats exposed to nicotine as adolescents. Pharmacol Biochem Behav 75: 355-361.
46. Malin DH, (2001) Nicotine dependence: studies with a laboratory model. Pharmacol Biochem Behav 70: 551-559.
47. Irvine EE, Cheeta S, File SE, (2001) Tolerance to nicotine's effects in the elevated plus-maze and increased anxiety during withdrawal. Pharmacol Biochem Behav 68: 319-325.
48. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ, (1997) LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats. Neuropharmacology 36: 1511-1516.
49. Helton DR, Modlin DL, Tizzano JP, Rasmussen K, (1993) Nicotine withdrawal: a behavioral assessment using schedule controlled responding, locomotor activity, and sensorimotor reactivity. Psychopharmacology (Berl) 113: 205-210.
50. Gonzalez S, Cascio MG, Fernandez-Ruiz J, Fezza F, Di Marzo V, et al. (2002) Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 954: 73-81.
51. Forget B, Coen KM, Le Foll B, (2009) Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration-comparison with CB(1) receptor blockade. Psychopharmacology (Berl) 205: 613-624.
52. Solinas M, Scherma M, Tanda G, Wertheim CE, Fratta W, et al. (2007) Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide. J Pharmacol Exp Ther 321: 1127-1134.
53. Scherma M, Medalie J, Fratta W, Vadivel SK, Makriyannis A, et al. (2008) The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology 54: 129-140.
54. Piomelli D, (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4: 873-884.
55. Haller J, Barna I, Barsvari B, Gyimesi Pelczer K, Yasar S, et al. (2009) Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. Psychopharmacology (Berl) 204: 607-616.
56. Patel S, Hillard CJ, (2006) Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318: 304-311.
57. Moreira FA, Kaiser N, Monory K, Lutz B, (2008) Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 54: 141-150.
58. Lisboa SF, Resstel LB, Aguiar DC, Guimaraes FS, (2008) Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. Eur J Pharmacol 593: 73-78.
59. Del Arco I, Navarro M, Bilbao A, Ferrer B, Piomelli D, et al. (2002) Attenuation of spontaneous opiate withdrawal in mice by the anandamide transport inhibitor AM404. Eur J Pharmacol 454: 103-104.
60. Stella N, Piomelli D, (2001) Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur J Pharmacol 425: 189-196.
61. Swanson LW, Petrovich GD, (1998) What is the amygdala? Trends Neurosci 21: 323-331.
62. Panagis G, Hildebrand BE, Svensson TH, Nomikos GG, (2000) Selective c-fos induction and decreased dopamine release in the central nucleus of amygdala in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Synapse 35: 15-25.
63. Tzavara ET, Monory K, Hanoune J, Nomikos GG, (2002) Nicotine withdrawal syndrome: behavioural distress and selective up-regulation of the cyclic AMP pathway in the amygdala. Eur J Neurosci 16: 149-153.
64. Sarnyai Z, Shaham Y, Heinrichs SC, (2001) The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev 53: 209-243.
65. Merlo Pich E, Lorang M, Yeganeh M, Rodriguez de Fonseca F, Raber J, et al. (1995) Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 15: 5439-5447.
66. Richter RM, Weiss F, (1999) In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administering rats. Synapse 32: 254-261.
67. Rodriguez de Fonseca F, Carrera MR, Navarro M, Koob GF, Weiss F, (1997) Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276: 2050-2054.
68. Bruijnzeel AW, Zislis G, Wilson C, Gold MS, (2007) Antagonism of CRF receptors prevents the deficit in brain reward function associated with precipitated nicotine withdrawal in rats. Neuropsychopharmacology 32: 955-963.
69. George O, Ghozland S, Azar MR, Cottone P, Zorrilla EP, et al. (2007) CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats. Proc Natl Acad Sci U S A 104: 17198-17203.
70. Patel S, Roelke CT, Rademacher DJ, Hillard CJ, (2005) Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur J Neurosci 21: 1057-1069.
71. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, et al. (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530-534.
72. Semba J, Wakuta M, Maeda J, Suhara T, (2004) Nicotine withdrawal induces subsensitivity of hypothalamic-pituitary-adrenal axis to stress in rats: implications for precipitation of depression during smoking cessation. Psychoneuroendocrinology 29: 215-226.
73. Viveros MP, Marco EM, Llorente R, Lopez-Gallardo M, (2007) Endocannabinoid system and synaptic plasticity: implications for emotional responses. Neural Plast 2007: 52908.